Who owns Kymera Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KYMR from SEC Form 13F filings across 302 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 302 institutions disclosed 98.9M shares of Kymera Therapeutics, Inc. worth $11.07B — about 98.8% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
302
13F holders
$11.07B
value, 2026 filers
98.8%
of shares outstanding (98.9M sh)
51
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of KYMR's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 12.6M | $1.41B | 0.1% | 12.6% | +1.8% |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 8.7M | $975.5M | 0.1% | 8.7% | +22.7% |
| 3 | BAKER BROS. ADVISORS LP | 8.7M | $967.8M | 4.6% | 8.6% | 0.0% |
| 4 | Avoro Capital Advisors LLC | 7.5M | $835.6M | 8.6% | 7.5% | 0.0% |
| 5 | BlackRock, Inc. | 5.8M | $651.2M | 0.0% | 5.8% | +5.2% |
| 6 | T. Rowe Price Investment Management, Inc. | 5.7M | $641.3M | 0.5% | 5.7% | -8.3% |
| 7 | BVF INC/IL | 3.9M | $432.9M | 14.2% | 3.9% | 0.0% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 3.7M | $414.4M | 0.1% | 3.7% | +0.9% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $340.3M | 0.0% | 3% | +3.8% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.0M | $333.0M | 0.0% | 3% | -0.5% |
| 11 | Atlas Venture Life Science Advisors, LLC | 2.8M | $318.3M | 50.4% | 2.8% | 0.0% |
| 12 | Siren, L.L.C. | 2.8M | $311.3M | 7.4% | 2.8% | -5.1% |
| 13 | STATE STREET CORP | 2.6M | $288.8M | 0.0% | 2.6% | -5.6% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.9M | $214.0M | 0.0% | 1.9% | +5.4% |
| 15 | GOLDMAN SACHS GROUP INC | 1.2M | $135.1M | 0.0% | 1.2% | +1.8% |
| 16 | Capital Research Global Investors | 1.1M | $126.4M | 0.0% | 1.1% | -18.6% |
| 17 | UBS Group AG | 1.0M | $115.6M | 0.0% | 1% | +2.6% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 886,951 | $99.2M | 0.0% | 0.9% | +67.4% |
| 19 | ALLIANCEBERNSTEIN L.P. | 819,071 | $91.6M | 0.0% | 0.8% | -16.6% |
| 20 | Driehaus Capital Management LLC | 808,098 | $90.3M | 0.6% | 0.8% | -12.1% |
| 21 | Merck & Co., Inc. | 772,165 | $86.3M | 10.5% | 0.8% | 0.0% |
| 22 | FEDERATED HERMES, INC. | 747,432 | $83.6M | 0.1% | 0.7% | -0.3% |
| 23 | Holocene Advisors, LP | 721,687 | $80.7M | 0.2% | 0.7% | +13.4% |
| 24 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 702,329 | $78.5M | 0.0% | 0.7% | -4.7% |
| 25 | DIMENSIONAL FUND ADVISORS LP | 693,290 | $77.5M | 0.0% | 0.7% | -7.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.